Aethlon Medical, Inc. AEMD), a pioneer in
developing therapeutic devices for infectious disease, announced today
that it has submitted a cancer research grant application entitled
"Tumor Exosome Removal to Stimulate Cancer-Specific Immunity." The
grant was submitted to the National Institute of Health (NIH) and
directed to the National Cancer Institute as a Phase I Small Business
Innovation Grant. A review and formal response to the grant
application is expected from the NIH in August. The grant application
discusses the potential use of the Aethlon Hemopurifier(TM )as a
method to remove exosomes that suppress the immune response in cancer
patients. Significant levels of immune-suppressive exosomes are
identified in cancer patients, whereas healthy individuals maintain
negligible levels. Aethlon proposes to improve the immune response to
malignancies by reducing the presence of tumor-derived exosomes,
thereby activating immunity to cancers. There is no assurance that
Aethlon will derive grant income related to this research initiative.
About Aethlon Medical
Aethlon Medical is developing the first medical device to treat
infectious disease. The device, known as the Hemopurifier(TM), is a
broad-spectrum treatment countermeasure against drug and vaccine
resistant bioweapons, naturally evolving pandemic threats such as H5N1
Avian Flu, and chronic infectious disease targets including
Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Aethlon
has also initiated research on a second generation Hemopurifier(TM)
that targets the capture of growth factors inherent in the spread of
Cancer. More information on Aethlon Medical and the Hemopurifier(TM)
technology can be found at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and
involve risks and uncertainties. Such forward-looking statements
involve assumptions, known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or
achievements of Aethlon Medical, Inc to be materially different from
any future results, performance, or achievements expressed or implied
by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, the Company's ability to
raise capital when needed, the Company's ability to complete the
development of its planned products, the ability of the Company to
obtain FDA and other regulatory approvals permitting the sale of its
products, the Company's ability to manufacture its products and
provide its services, the impact of government regulations, patent
protection on the Company's proprietary technology, product liability
exposure, uncertainty of market acceptance, competition, technological
change, and other risk factors. In such instances, actual results
could differ materially as a result of a variety of factors, including
the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and
Exchange Commission filings.
KEYWORD: NORTH AMERICA CALIFORNIA UNITED STATES
INDUSTRY KEYWORD: GOVERNMENT GOVERNMENT AGENCIES HEALTH MEDICAL DEVICES ONCOLOGY PHARMACEUTICAL
SOURCE: Aethlon Medical, Inc.
CONTACT INFORMATION:
Aethlon Medical, Inc.
Jeff Richardson, 858.459.7800 x302
jrichardson@aethlonmedical.com
James A. Joyce, 858.459.7800 x301
jj@aethlonmedical.com
A True Wise Person Realizes How Much They DON’T Know, Rather Than How Much They DO..
